Literature DB >> 7904986

Number of simultaneously expressed enzyme alterations correlates with progression of N-ethyl-N-hydroxyethylnitrosamine-induced hepatocarcinogenesis in rats.

S Yamaguchi1, K Hakoi, K Ozaki, T Kato, D Tiwawech, S Nagao, H Takahashi, K Matsumoto, H Tsuda.   

Abstract

Preneoplastic and neoplastic liver cell lesions, induced by EHEN (N-ethyl-N-hydroxyethylnitrosamine) in rats, were investigated to establish the numbers of simultaneously expressed altered enzyme phenotypes within the lesion cells. The lesions were divided into 5 classes on the basis of altered expression in one or more of the following 5 enzymes: glutathione S-transferase placental form, glucose-6-phosphate dehydrogenase, glucose-6-phosphatase, adenosine triphosphatase, and gamma-glutamyl transpeptidase. Class 1 lesions contained cells expressing one altered enzyme. Similarly, class 2, 3, 4 and 5 lesions had cells simultaneously expressing 2, 3, 4, and 5 enzyme alterations, respectively. Four histopathological categories of lesions, ACF (altered cell foci) (274 lesions), HN (hyperplastic nodules) (47 lesions), HCC (hepatocellular carcinomas) (99 lesions) and THC (transplanted hepatocellular carcinomas) (5 lesions) were studied. Proliferation potential was assessed in terms of 5-bromo-2'-deoxyuridine (BrdU) incorporation. The distribution profiles of classes 1 to 5 showed a clear reciprocal change from low class (1 to 2 enzymes) predominance in ACF to high class (4 to 5 enzymes) predominance in HN. Increase of BrdU labeling indices was clearly correlated with progression from HN to HCC. Only a small population of class 5 ACF showed a high BrdU labeling index, indicating particular potential for further development. Thus, the stages of EHEN-induced neoplasia were found to be characterized by gradual increase in the number of altered enzyme phenotypes, with acquisition of proliferative potential being associated with further progression towards malignant conversion.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7904986      PMCID: PMC5919116          DOI: 10.1111/j.1349-7006.1993.tb02828.x

Source DB:  PubMed          Journal:  Jpn J Cancer Res        ISSN: 0910-5050


N‐ethy‐N‐hydroxyethylnitrosamine glutathione S‐transferase placental form glucose‐6‐phosphate dehydrogenase glucose‐6‐phosphatase adenosine triphosphatase γ‐glutamyl transpeptidase altered cell foci hyperplastic nodules hepatocellular carcinomas transplanted hepatocellular carcinomas 5‐bromo‐2′‐deoxyuridine
  33 in total

Review 1.  Glutathione transferases as markers of preneoplasia and neoplasia.

Authors:  K Sato
Journal:  Adv Cancer Res       Date:  1989       Impact factor: 6.242

2.  Quantitative histochemical and autoradiographic studies of hepatocarcinogenesis in rats fed 2-acetylaminofluorene followed by phenobarbital.

Authors:  T D Pugh; S Goldfarb
Journal:  Cancer Res       Date:  1978-12       Impact factor: 12.701

3.  Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures.

Authors:  S M Hsu; L Raine; H Fanger
Journal:  J Histochem Cytochem       Date:  1981-04       Impact factor: 2.479

4.  Relative merits of immunohistochemical demonstrations of placental, A, B and C forms of glutathione S-transferase and histochemical demonstration of gamma-glutamyl transferase as markers of altered foci during liver carcinogenesis in rats.

Authors:  M Tatematsu; Y Mera; N Ito; K Satoh; K Sato
Journal:  Carcinogenesis       Date:  1985-11       Impact factor: 4.944

5.  Quantitative stereological evaluation of four histochemical markers of altered foci in multistage hepatocarcinogenesis in the rat.

Authors:  S Hendrich; H A Campbell; H C Pitot
Journal:  Carcinogenesis       Date:  1987-09       Impact factor: 4.944

6.  Enhancement of NNM-induced carcinogenesis in the rat liver by phenobarbital: a combined morphological and enzyme histochemical approach.

Authors:  M A Moore; H J Hacker; H W Kunz; P Bannasch
Journal:  Carcinogenesis       Date:  1983       Impact factor: 4.944

7.  Induction of gamma-glutamyl transpeptidase activity by dietary phenobarbital in "spontaneous" hepatic tumors of C3H mice.

Authors:  T Kitagawa; R Watanabe; H Sugano
Journal:  Gan       Date:  1980-08

8.  Quantitative stereologic study of the effects of varying the time between initiation and promotion on four histochemical markers in rat liver during hepatocarcinogenesis.

Authors:  Y H Xu; R Maronpot; H C Pitot
Journal:  Carcinogenesis       Date:  1990-02       Impact factor: 4.944

9.  Effects of modifying agents on conformity of enzyme phenotype and proliferative potential in focal preneoplastic and neoplastic liver cell lesions in rats.

Authors:  H Tsuda; K Ozaki; S Uwagawa; S Yamaguchi; K Hakoi; T Aoki; T Kato; K Sato; N Ito
Journal:  Jpn J Cancer Res       Date:  1992-11

10.  Dose-dependent induction of liver and thyroid neoplastic lesions by short-term administration of 2-amino-3-methylimidazo[4,5-f]quinoline combined with partial hepatectomy followed by phenobarbital or low dose 3'-methyl-4-dimethylaminoazobenzene promotion.

Authors:  H Tsuda; M Asamoto; T Ogiso; T Inoue; N Ito; M Nagao
Journal:  Jpn J Cancer Res       Date:  1988-06
View more
  3 in total

1.  A Liver Index and its Relationship to Indices of HCC Aggressiveness.

Authors:  Brian I Carr; Vito Guerra; Edoardo G Giannini; Fabio Farinati; Francesca Ciccarese; Gian Ludovico Rapaccini; Maria Di Marco; Luisa Benvegnù; Marco Zoli; Franco Borzio; Eugenio Caturelli; Alberto Masotto; Franco Trevisani
Journal:  J Integr Oncol       Date:  2016-09-05

2.  Transgenic rats carrying human c-Ha-ras proto-oncogene are highly susceptible to N-nitrosomethylbenzylamine induction of esophageal tumorigenesis.

Authors:  Makoto Asamoto; Hiroyasu Toriyama-Baba; Takamasa Ohnishi; Akihiro Naito; Tomonori Ota; Akira Ando; Takahiro Ochiya; Hiroyuki Tsuda
Journal:  Jpn J Cancer Res       Date:  2002-07

3.  Hepatocyte growth factor enhancement of preneoplastic hepatic foci development in rats treated with diethylnitrosamine and N-ethyl-N-hydroxyethylnitrosamine.

Authors:  M Yaono; R Hasegawa; Y Mizoguchi; M Futakuchi; T Nakamura; N Ito; T Shirai
Journal:  Jpn J Cancer Res       Date:  1995-08
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.